Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines
Episode
65 min
Read time
3 min
Topics
Relationships, Investing, Fundraising & VC
AI-Generated Summary
Key Takeaways
- ✓Fast-follower differentiation: Kailera's lead injectable rebutatide achieves comparable or superior weight loss to Eli Lilly's tirzepatide at less than half the dose, with a similar GI tolerability profile. Phase 2 data showed 23-24% weight loss from baseline at 8mg doses. Entering a crowded market later can still succeed—Lipitor was the sixth or seventh statin and became the best-selling drug in history.
- ✓High-BMI unmet need: Two-thirds of patients starting with a BMI above 35 on currently marketed GLP-1 drugs still have a BMI of 30 or higher after completing therapy. Kailera targets this population specifically, positioning rebutatide as a tool to achieve meaningful weight reduction before transitioning patients to an oral maintenance therapy, addressing a gap the existing market leaders have not fully closed.
- ✓China partnership model: Licensing assets from Hengrui gives Kailera a temporal advantage—Hengrui continues generating clinical data in China ahead of Kailera's US trials, allowing risk-adjusted pipeline decisions. Kailera's supply chain is CDMO-based and almost entirely US-located. This structure lets a Western company benefit from China's clinical speed while maintaining regulatory credibility with the FDA and European agencies.
- ✓Portfolio strategy across routes of administration: Kailera is advancing four candidates: rebutatide injectable (Phase 3), an oral peptide version of rebutatide (Phase 2 in 2025), an oral small molecule GLP-1 agonist (Phase 2 in 2025), and a triple GLP-1/GIP/glucagon agonist (Phase 1 target in 2025). This multi-route approach lets the company address patients at different stages of their obesity treatment journey, from initial weight loss to long-term maintenance.
- ✓Triple-G mechanism for liver disease: Adding a glucagon receptor agonist to the GLP-1/GIP dual mechanism creates a triple agonist that may directly reduce liver fat, targeting metabolic-associated steatohepatitis. Kailera's triple-G candidate is in early development. Competitor triple-G data has already shown signals in knee osteoarthritis. This mechanism could expand the addressable patient population well beyond obesity into serious liver disease.
What It Covers
Ron Renaud, CEO of Kailera Therapeutics, explains how his company is building a GLP-1 obesity drug portfolio around licensed assets from China's Jiangsu Hengrui Pharmaceuticals. With $1 billion raised and Phase 3 trials underway, Kailera's lead injectable candidate targets patients with BMI above 35, aiming for best-in-class weight loss by 2029.
Key Questions Answered
- •Fast-follower differentiation: Kailera's lead injectable rebutatide achieves comparable or superior weight loss to Eli Lilly's tirzepatide at less than half the dose, with a similar GI tolerability profile. Phase 2 data showed 23-24% weight loss from baseline at 8mg doses. Entering a crowded market later can still succeed—Lipitor was the sixth or seventh statin and became the best-selling drug in history.
- •High-BMI unmet need: Two-thirds of patients starting with a BMI above 35 on currently marketed GLP-1 drugs still have a BMI of 30 or higher after completing therapy. Kailera targets this population specifically, positioning rebutatide as a tool to achieve meaningful weight reduction before transitioning patients to an oral maintenance therapy, addressing a gap the existing market leaders have not fully closed.
- •China partnership model: Licensing assets from Hengrui gives Kailera a temporal advantage—Hengrui continues generating clinical data in China ahead of Kailera's US trials, allowing risk-adjusted pipeline decisions. Kailera's supply chain is CDMO-based and almost entirely US-located. This structure lets a Western company benefit from China's clinical speed while maintaining regulatory credibility with the FDA and European agencies.
- •Portfolio strategy across routes of administration: Kailera is advancing four candidates: rebutatide injectable (Phase 3), an oral peptide version of rebutatide (Phase 2 in 2025), an oral small molecule GLP-1 agonist (Phase 2 in 2025), and a triple GLP-1/GIP/glucagon agonist (Phase 1 target in 2025). This multi-route approach lets the company address patients at different stages of their obesity treatment journey, from initial weight loss to long-term maintenance.
- •Triple-G mechanism for liver disease: Adding a glucagon receptor agonist to the GLP-1/GIP dual mechanism creates a triple agonist that may directly reduce liver fat, targeting metabolic-associated steatohepatitis. Kailera's triple-G candidate is in early development. Competitor triple-G data has already shown signals in knee osteoarthritis. This mechanism could expand the addressable patient population well beyond obesity into serious liver disease.
- •Obesity as a platform disease: GLP-1 therapies are showing effects beyond weight loss, including a 20% reduction in cardiovascular disease risk, reduced chronic kidney disease risk, and anecdotal reductions in compulsive behaviors like gambling and alcohol consumption. Renaud frames obesity treatment as analogous to statins—a preventive platform where payers will eventually recognize long-term cost savings, making the reimbursement case stronger over time.
Notable Moment
Renaud notes that global obesity has now surpassed global hunger according to UNICEF data, reframing the scale of the problem Kailera is addressing. He also points out that declining fast food sales, soda consumption, and alcohol purchases may not be coincidental given the millions of patients now on GLP-1 therapies.
Episode Transcript
Welcome to the Long Run. This is a podcast for biotech adventurers. I'm your host, Luke Timmerman. Today's guest is Ron Renaud. Ron is the CEO of Waltham, Massachusetts based Kilera Therapeutics. Kilera is pursuing what could be the biggest opportunity in pharmaceutical industry history. It's developing a portfolio of GLP one based drugs for obesity. Drugs in this category have been around a long time for the treatment of type two diabetes, but over the last few years, demand has skyrocketed. That's because evidence has been mounting that these drugs are effective at helping all kinds of people, not just diabetics, to lose significant weight and lower their risk for a bunch of chronic ailments that stem from obesity, like cardiovascular disease and chronic kidney disease for starters. More than one billion people worldwide are considered obese. Eli Lilly and Novo Nordisk are the category leaders, and their success has inspired an estimated 70 or 80 different drugs and drug combinations sprinting ahead in clinical development. Dozens of public and private companies are striving to capture a piece of the market. Some analysts estimate it will be worth more than a $150,000,000,000 a year in sales by the early twenty thirties. They're seeking to differentiate in various ways with different tolerability profiles, magnitude of weight loss, convenience with oral pills, less frequent injections, and different scientific ways of working. Others are thinking of ways to reduce costs and reduce side effects like nausea, vomiting, and muscle loss. KILERA is one of the well funded and aggressive entrants in the category. It has raised a billion dollars in a pair of venture capital rounds. The money is being used to advance a portfolio of injectable and oral drug candidates from China based, Jiangsu Hangre Pharmaceuticals. Kynilera is now running a series of global phase three clinical trials with a lead candidate that seeks to compete with Lilly's blockbuster Tirzepatide marketed as Zepbound for obesity. Ron has a long and diversified track record of success in biotech, which brings him to this challenge. He was previously CEO of a hepatitis c drug developer acquired by Merck, a messenger RNA therapeutics developer acquired by Sanofi, and a neuro science drug developer acquired by AbbVie. If Kailera's drug candidates can pass muster in clinical development, it stands a chance to make the biggest health impact of all. Ron and his colleagues think Kailera's lead candidate, k a I ninety five thirty one, could deliver best in class weight loss for patients with body mass index of thirty five and above. Now before we get started, a word from the newest sponsor of the long run, AlphaSense. As I was preparing for this conversation with one of the leading entrepreneurs in the obesity field, Ron Renaud, I ran a quick search in AlphaSense. It's the AI platform a lot of biotech analysts and investors use to get insights fast, kind of like having an analyst that never sleeps. Kailera operates in one of the …
Get the full transcript (11,570 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 62-minute episode.
Get The Long Run with Luke Timmerman summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from The Long Run with Luke Timmerman
Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
Sep 9 · 96 min
Beyond Biotech
Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases
Apr 24
More from The Long Run with Luke Timmerman
Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus
Aug 25 · 67 min
Biotech 2050 Podcast
John Lepore, CEO & President - ProFound Therapeutics, on Proteome, AI, & Bold First-in-Class Drugs
Dec 3
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links.
company
“Ron Renaud, CEO of Kailera Therapeutics, explains how his company is building a GLP-1 obesity drug portfolio around licensed assets from China's Jiangsu Hengrui Pharmaceuticals.”
“Kailera's lead injectable candidate targets patients with BMI above 35, aiming for best-in-class weight loss by 2029. With $1 billion raised and Phase 3 trials underway, Kailera's lead injectable rebutatide achieves comparable or superior weight loss”
“Kailera's lead injectable rebutatide achieves comparable or superior weight loss to Eli Lilly's tirzepatide at less than half the dose, with a similar GI tolerability profile.”
More from The Long Run with Luke Timmerman
We summarize every new episode. Want them in your inbox?
Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus
Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases
Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
Similar Episodes
Related episodes from other podcasts
Beyond Biotech
Apr 24
Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases
Biotech 2050 Podcast
Dec 3
John Lepore, CEO & President - ProFound Therapeutics, on Proteome, AI, & Bold First-in-Class Drugs
The RTW Podcast
Aug 12
Revolutionizing RNA therapeutics - Avidity Biosciences
David Senra
Aug 2
Micky Malka, Founder of Ribbit Capital
Beyond Biotech
Jul 24
This nonprofit is building the ecosystem to cure epidermolysis bullosa
Explore Related Topics
This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Investing & Markets Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into The Long Run with Luke Timmerman.
Every Monday, we deliver AI summaries of the latest episodes from The Long Run with Luke Timmerman and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime